This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

RxHealth Value supports the FTC's proposed study of generic drug competition

( December 18, 2000, 23:31 GMT | Official Statement) -- MLex Summary: RxHealth Value supports the US Federal Trade Commission's investigation of the possible anticompetitive activities of pharmaceutical manufacturers in using the 30-month stay and the 180-day marketing exclusivity provision of the Hatch-Waxman Act. RxHealth also supports further study of cases where manufacturers of brand-name drug products have entered into anticompetitive agreements with generic manufacturers to delay or eliminate specific generic drug products' entrance.See the public comment in full below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections